SWKH News and Press, SWK Holdings Corporation From 03/31/21

SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2020 Specialty Finance Portfolio Growth, Underlying Credit Performance Highlight Strong 2020 Conference Call and Live Audio Webcast Scheduled for Thursday, April 1, 2021 at 10:00 a.m. ET ...

Acerus Pharmaceuticals ([[ASPCF]]) announces that it has entered into an amended agreement related to its existing credit facility with SWK Funding, a subsidiary of SWK Holdings Corporation ([[SWKH]] -2.1%).The amendments set principal repayment at $1.1M for May 15, 2021 followed by quarterly...

TORONTO, March 26, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today announced that it has entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“...

Sincerus Pharmaceuticals Completes Financing With SWK To Support The Demand For Its Customized Dermatologic Medicines PR Newswire POMPANO BEACH, Fla. , March 24, 2021 /PRNewswire/ -- Sincerus Pharmaceuticals, the parent company of Prescriber's Choice and Sin...

Enteris BioPharma Announces Dr. Gary Shangold to Host Webinar on Utilization of 505(b)(2) Regulatory Pathway in Drug Development PR Newswire BOONTON, N.J. , March 16, 2021 /PRNewswire/ -- Enteris BioPharma, Inc. , a biotechnology company developing innovative...

Enteris BioPharma to Host Webinar on Strategies for Initiating Phase 1 Clinical Development with Limited API PR Newswire BOONTON, N.J. , Jan. 12, 2021 /PRNewswire/ -- Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products built ...

Biotechnology company Enteris BioPharma, wholly owned subsidiary of SWK Holdings ([[SWKH]] +0.2%), forecasts growth opportunities this year and says that it will actively pursue partnership discussions with companies seeking US domestic CDMO capabilities.Will advance activities...

Enteris BioPharma Highlights 2020 Achievements and 2021 Outlook Enteris poised to capitalize on multiple value building opportunities involving Peptelligence® and ProPerma™ platforms PR Newswire BOONTON, N.J. , Jan. 7, 2021 /PRNewswire/ -- ...

Flowonix Medical, Inc. and SWK Holdings Corporation Announce Closing of $33 Million Financing PR Newswire MOUNT OLIVE, N.J. , Jan. 4, 2021 /PRNewswire/ -- Flowonix Medical, Inc., a medical device company focused on providing advanced, implantable drug delive...

SWK Holdings' (SWKH) wholly-owned subsidiary, Enteris BioPharma received a second milestone payment of $2.5M from Cara Therapeutics (CARA) with regards the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA.According to the contractual splits ag...